RT Journal Article
SR Electronic
T1 In vitro susceptibility of mycobacterium bovis against moxifloxacin
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p4417
VO 38
IS Suppl 55
A1 Timo Weiss
A1 Torsten Blum
A1 Jens Kollmeier
A1 Harald Mauch
A1 Holger Russmann
A1 Nicolas Schönfeld
A1 Torsten T. Bauer
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p4417.abstract
AB Introduction: Mycobacterium bovis, the causative agent of bovine tuberculosis is also responsible for diseases in humans. To date there are no data available on the in vitro susceptibility of M. bovis strains to moxifloxacin, an established second line drug in the treatment of disease caused by M. tuberculosis.Methods: From M. bovis-positive cultures from BAL, sputum, pleural effusion or cerebrospinal fluid of 34 pts from the years 1993-2010, we retrospectively evaluated the sensitivity in vitro and the minimum inhibitory concentrations of moxifloxacin. Culturing and resistance testing was performed on solid Middlebrook agar plates.Results: Out of 34 tested M. bovis-positive cultures 33 showed a sensitivity to moxifloxacin at 2 or 4 mcg/ml. Only one strain showed resistance.Conclusion: Our study of a small group of patients shows a high sensitivity rate of moxifloxacin against M. bovis strains. Despite the absence of clinical treatment studies, we see a potential use of moxifloxacin as a second line drug, with regular ineffectiveness of the first-line drug pyrazinamide in M. bovis.